EUCTR2008-000743-34-IT进行中（未招募）不适用
Studio di Fase II multicentrico, randomizzato, in doppio cieco, controllato verso placebo, parallel-dose di R935788 in pazienti affetti da artrite reumatoide che hanno sperimentato fallimento di almeno un biologico - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 195
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •) Patients must give written informed consent by signing an IRB/EC-approved Informed Consent Form (ICF) prior to admission to this study. 2) Males and females, 18 years of age or older, with active RA for at least 12 months prior to Day 1 dosing (functional class I?III, e.g., not bed or wheelchair-bound) Active RA is defined as the presence of (a) ≥ 6 swollen joints (28 joint count); AND (b) ≥ 6 tender joints (28 joint count); AND at least one of the following (c) ESR >28 mm/hr or CRP >ULN for the central reference laboratory. 3) Are currently receiving or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept, or anakinra at an approved labeled dose for ≥3 months prior to Day 1 dosing and are designated as biologic therapy failures for lack of efficacy, safety, or tolerability. 4) Patients may receive stable doses of methotrexate (MTX), azathioprine (not in combination with MTX), leflunomide (not in combination with MTX), sulfasalazine, chloroquine, hydroxychloroquine, gold, NSAIDs (including COX2 inhibitors), minocycline, or doxycycline. The dose must have been stable for at least 30 days prior to Day 1 dosing and must not be changed during the washout, screening and treatment periods, unless dictated by tolerability requirements. Patients who are taking MTX must have been receiving weekly MTX doses (7.5?25 mg/week) for a minimum of 3 months prior to Day 1 dosing and must be receiving a stable MTX dose, with no change in route, for the previous 6 weeks prior to Day 1 dosing. Patients who are receiving MTX must also be receiving folic or folinic acid supplementation at a stable dose for at least 6 weeks prior to Day 1 dosing. 5) Females of childbearing potential must be fully informed of the potential for R788 to adversely affect the fetus and, if sexually active, must agree to use a well established method of birth control during the study (oral contraceptive, mechanical barrier, long acting hormonal agent). These patients must not be lactating and must have a negative urine pregnancy test at the time of randomization and at each laboratory determination. 6) The patient must otherwise be in good health as determined by the Investigator on the basis of medical history, physical examination, and laboratory screening tests during the screening period. See exclusion criteria for specific exclusions. 7) In the Investigator?s opinion, the patient has the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) The patient has a history of, or a concurrent, clinically significant illness, medical condition (other than arthritis) or laboratory abnormality that, in the Investigator?s opinion, could affect the conduct of the study. Specifically, excluded are patients with the following: a) uncontrolled or poorly controlled hypertension; b) other autoimmune disease (psoriatic arthritis, lupus, mixed connective disorder) or arthritis syndromes (gout, Lyme disease, Reiter?s syndrome); c) recent (within past 2 months prior to Day 1 dosing) serious surgery or infectious disease; d) recent history (past 5 years prior to Day 1 dosing) of, or treatment for, a malignancy other than nonmelanomatous skin cancer, or any history of lymphoma; e) Hepatitis B surface antigen positive; f) Hepatitis C antibody positive; may be included if Hepatitis C RIBA negative or HCV RNA negative (qualitative); g) interstitial pneumonitis or active pulmonary infection on chest x-ray (taken within 1 month prior to screening); h) Tuberculosis (TB): the TB skin test should be negative (if the patient was never vaccinated, or if vaccinated more than 10 years ago; in this context negative means < 5 mm induration); if the TB skin test is positive (in an unvaccinated patient), an appropriate prophylactic anti-TB regimen must be documented: Patients should have completed anti-TB treatment 1 year prior to Day 1 dosing. For vaccinated patients, if the vaccination was less than 10 years ago and the skin test is positive, an exception may be requested if the induration is < 10mm, the chest x-ray shows no sign of TB as confirmed by a radiologist, or the patient has had a course of Isoniazid (or comparable regimen). i) known laboratory abnormalities: ALT > 1.2x ULN, creatinine >1.5x ULN, an ANC < 2,500/mm3 or lymphocyte count < 600/mm3, Hgb <9 g/dL, platelet count < 125,000/mm3 are excluded. 2) The patient has a history of substance abuse, drug addiction or alcoholism. Patients may consume up to 4 units of alcohol per week; however, alcohol should be avoided in the 72 hours prior to lab assessments. Patients who cannot reliably comply with this should be excluded. A unit of alcohol is defined as the following: Beer=12 oz or 355 mL; wine = 5 oz or 148 mL; sweet dessert wine=3 oz or 89 mL; 80 proof distilled spirits= 1.5 oz or 44 mL. 3) The patient has been treated previously treated with R788 under a different protocol. 4) The patient has a pacemaker, aneurysm clip or other contraindication to MRI.
研究者
相似试验
进行中（未招募）
1 期
Etude de phase II randomisée, multicentrique, en ouvert, évaluant l'efficacité de l’association Avastin (bevacizumab) + Torisel (temsirolimus) versus Sutent (sunitinib) versus Avastin+ Roféron(interféron alpha-2a) en première ligne de traitement du cancer du rein métastatique - TORAVAPatient en 1ère ligne de traitement d'un cancer du rein métastique.MedDRA version: 9.1Level: LLTClassification code 10050076Term: Metastatic renal carcinomaEUCTR2007-003369-42-FRCENTRE LEON BERARD
进行中（未招募）
1 期
Estudio de fase IIa, multicéntrico, randomizado, doble ciego, controlado con placebo, de cohortes secuenciales, de búsqueda de rango de dosis para evaluar la seguridad, tolerabilidad y el efecto clínico de escalada de dosis de laquinimod en la Enfermedad de Crohn activa de moderada a grave.Enfermedad de Crohn activa de moderada a graveMedDRA version: 9.1Level: PTClassification code 10011401Term: Crohn's diseaseEUCTR2008-004276-49-ESTeva Pharmaceutical Industries Ltd.199
招募中
1 期
Treatment with the investigational drug BST-236 of patients ineligible for intensive chemotherapy with high-risk myelodysplastic syndrome or acute myeloid leukaemia who did not respond or relapsed after first-line treatment.Patients unfit for intensive chemotherapy with AML or HR MDS that failed or relapsed following first line therapyMedDRA version: 21.1Level: LLTClassification code 10081514Term: Acute myeloid leukemia refractorySystem Organ Class: 100000004864MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2020-003400-13-ITGroupe Francophone des Myelodysplasies40
进行中（未招募）
1 期
Étude multicentrique de phase II randomisée, évaluant l’efficacité de l’anastrozole et du fulvestrant dans le traitement néo-adjuvant du cancer du sein opérable chez les femmes ménopausées et ayant pour objectif l'identification de profils d’hormonosensibilité. - NIMFEAAdénocarcinome mammaire infiltrant non métastatique, opérable et non conservable d’emblée, survenant chez des patientes ménopausées RH+.MedDRA version: 9.1 Level: LLT Classification code 10006188 Term: Breast cancer female NOSEUCTR2006-006409-10-FRFédération Nationale des Centres de Lutte Contre le Cancer120
进行中（未招募）
不适用
na fase II, ensayo multicentrico, randomizado, doble ciego, controlado por placebo que comparala eficacia y la tolerencia de Clonidine Lauriad 50 mcg y 100 mcg comprimido bucal mucoadhesivo administrado una vez por dia a un placebo en la prevencion y tratamiento de la mucositis oral inducidapor quimioterapia y radioterapia en pacientes con cancer de cabeza y cuelloEUCTR2009-014870-16-ESBioAlliance Pharma183